logo-loader
viewSareum Holdings PLC

Sareum 'very excited' by TYK2 inhibitor results says chief scientific officer

Sareum Holdings Plc (LON:SAR) has successfully demonstrated the potential of one of its drug candidates to tackle a rare and difficult-to-treat form of leukaemia.

The TYK2 inhibitor was assessed as part of a feasibility study to see whether it might work in t-cell acute lymphoblastic leukaemia (T-ALL), which occurs in late childhood and early adolescence.

Chief scientific officer Dr John Reader tells Proactive: ''TYK2 is believed to play a role in the process by which cancer cells avoid cell death. It's a very important protein in the immune system so lots of the components of the immune system, which are generally the white blood cells, rely on TYK2 for their function.''

''What we're trying to develop here is a targeted therapy rather than using effectively poisons, which are what chemotherapy is - this is more of a rational approach where we're looking to tackle the Achilles heel of the cancer'', Dr Reader added.

The early-stage work was supported by Innovate UK and a grant of £140,000.

Quick facts: Sareum Holdings PLC

Price: 0.3315 GBX

AIM:SAR
Market: AIM
Market Cap: £10.18 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Sareum Holdings PLC named herein, including the promotion by the Company of Sareum Holdings PLC in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Investor Update: IQ-AI rockets as it receives StoneChecker FDA clearance

Headlines from the Proactive UK newsroom. IQ-AI (LON:IQAI) has received FDA clearance to market its StoneChecker Software in the US. IQ-AI said it was delighted with the decision. Synairgen (LON:SNG) is to present biomarker data from the first part of its ongoing Phase II trial of its...

on 27/9/19

2 min read